In the fifth edition of the “Classification of Central Nervous System Tumors,” IDHm-GBM has been redefined as “IDH-mutant astrocytoma, CNS WHO grade 4,” and GBM diagnosis is only applicable to IDHwt tumors, further establishing the central role of the IDH status in prognosis assessment.9 This evidence concerns the gene IDH1 and glioblastoma.